Skip to main content
OpenTrials
Completed

NCT Number: NCT02831166

Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

Primary percutaneous coronary intervention represents the gold standard for the treatment of ST-segment-elevation acute myocardial infarction. However, periprocedural bleedings are associated with an increased risk of mortality, re-infarction, and stroke. Although the prognostic value of access site related bleeding complications is still debated, transradial approach is associated with better short-term outcomes and reduced hospital stay as compared to transfemoral approach. The investigators aimed to compare transradial approach with transfemoral approach with systematic achievement of hemostasis by the implantation of a vascular closure device in a national multicentre randomized clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pedro Beraldo de Andrade

Marília, São Paulo, 17515900, Brazil

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;
  • Intention to perform primary percutaneous coronary intervention;
  • Signed informed consent;
  • Patient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process.

Exclusion criteria

  • Less than 18 years of age;
  • Pregnancy;
  • Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists;
  • Hypersensitivity to antiplatelet and/or anticoagulant drugs;
  • Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3);
  • Uncontrolled systemic hypertension;
  • Cardiogenic shock;
  • Previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft;
  • Documented chronic peripheral arterial disease preventing the use of the femoral technique;
  • Severe concomitant disease with life expectancy below 12 months;
  • Participation in drug or devices investigative clinical trials in the last 30 days;
  • Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.

Treatment and study plan

Transradial primary percutaneous coronary intervention

Procedure

Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.

Transfemoral primary percutaneous coronary intervention

Procedure

Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.

Primary outcomes

  1. Major vascular access site complications

    Time frame: 48 hours post-procedure

    Major vascular complications related to arterial access site will be evaluated during hospitalization by physical examination and duplex ultrassonography and include major bleeding, retroperitoneal hemorrhage, compartment syndrome, pseudoaneurysm, arteriovenous fistula, limb ischemia or need for vascular surgery repair.

Secondary outcomes

  1. Device success

    Time frame: 48 hours post-procedure

    The success of the device is defined as the attainment of adequate hemostasis at the end of the procedure, without the need to apply other compression methods.

Sponsors and collaborators

Lead sponsor

Irmandade Santa Casa Misericórdia Marília

Other

Registry information

Official study title

A Randomized Comparison Between Transfemoral Approach With Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention

Acronym: ARISE-2

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jul 13, 2016
Registry last updated
Feb 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.